While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Net Sales- Outside of the United States: $569.10 million compared to the $684.70 million average estimate based on three analysts. The reported number represents a change of -10.4% year over year. Net Sales- United States: $816.80 million versus the three-analyst average e ...

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.69 on $1.62 billion in revenues for the coming quarter and $2.77 on $6.56 billion in revenues for the current fiscal year. What's Next for Edwards Lifesciences? Edwards Lifesciences (EW) came out with quarterly earnings of $0.70 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.66 per share a year ago. These figures ...

Edwards Lifesciences Corporation (EW) announced its decision to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company. This follows Edwards Lifescience's initial investment in Innovalve in 2017, following which Innovalve has shown progress and early clinical success. The acquisition is set to bolster Edwards Lifesciences' existing mitral innovations, providing advanced TMVR solutions to address significant unmet needs in structural heart disease. Significan ...

Earnings Expectations - The market expects Edwards Lifesciences to report a year-over-year increase in earnings and revenues for the quarter ended June 2024 [1] - The company is expected to post quarterly earnings of $0.70 per share, representing a year-over-year change of +6.1% [2] - Revenues are expected to be $1.65 billion, up 8.1% from the year-ago quarter [12] Earnings ESP and Zacks Rank - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate being a more recent version of the consensus estimate [4] - A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [6] - Edwards Lifesciences currently has a Zacks Rank of 4 (Sell) [7] - The company's Earnings ESP is +0.58%, indicating that the Most Accurate Estimate is higher than the Zacks Consensus Estimate [23] Historical Performance and Estimate Revisions - For the last reported quarter, Edwards Lifesciences delivered a surprise of +3.13%, with actual earnings of $0.66 per share compared to the expected $0.64 [8] - Over the last four quarters, the company has beaten consensus EPS estimates two times [22] - The consensus EPS estimate for the quarter has been revised 0.14% lower over the last 30 days [21] Predictive Insights - Stocks with a positive Earnings ESP and a solid Zacks Rank produce a positive surprise nearly 70% of the time [6] - A positive or negative Earnings ESP reading theoretically indicates the likely deviation of actual earnings from the consensus estimate, but the model's predictive power is significant for positive ESP readings only [14] - It is difficult to predict an earnings beat with confidence for stocks with negative Earnings ESP readings and/or a Zacks Rank of 4 (Sell) or 5 (Strong Sell) [20] Market Reaction and Future Expectations - The stock might move higher if key numbers top expectations in the upcoming earnings report, expected to be released on July 24 [11] - Management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations [19]

Edwards Lifesciences Corporation (EW) is scheduled to report second-quarter 2024 results on Jul 24, after market close. Q2 Estimates The Zacks Consensus Estimate for second-quarter 2024 net earnings of 70 cents per share indicates a 6.1% improvement from the year-ago reported figure. Estimate Revision Trend Ahead of Earnings Let's briefly look at how things have progressed for the MedTech major leading up to this announcement. Similar to the last reported quarter, Edwards Lifesciences is likely to have gain ...

Vancouver, British Columbia--(Newsfile Corp. - June 19, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") announces that the Board of directors has determined that its in the best interest of the Company to return capital to its shareholders by way of a reduction in stated capital of the Company. On Behalf of the Board Further details in respect of the Capital Reduction, the Distribution and special general meeting matters will be announced when determined and will be provided in t ...

Edwards Lifesciences Corporation (EW) is well poised for growth in coming quarters, backed by the strength of a differentiated portfolio of advanced therapies. The company continues to witness strong performance of its SAPIEN 3 Ultra RESILIA platform, the leading platform in the United States and Japan. However, stiff rivalry and foreign exchange headwinds are a concern for EW's business. In the past six months, this Zacks Rank #3 (Hold) stock has gained 30.2% compared with an 18.1% rise of the industry and ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Edwards Lifesciences (EW) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Edwards Lifesciences is one of 1050 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

Have you looked into how Edwards Lifesciences (EW) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this medical device maker, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential ...